Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The primary purpose of this study is to determine the response rate of patients with recurrent platinum resistant ovarian cancer when treated with oral minoxidil. Secondary objectives include estimating the time to disease progression while on minoxidil and to describe the toxicities of minoxidil when used for patients with recurrent platinum resistant ovarian cancer. An exploratory objective is to evaluate if efficacy of minoxidil is improved in patients that have the Kir6/SUR complex versus those that do not.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Loyola University
• Collaborator: Cures Within Reach
• Treatments: Minoxidil

Criteria

Inclusion Criteria

• Participants must have recurrent platinum resistant ovarian cancer. Histologic documentation of the recurrence is not required.

• Participants must have platinum resistant disease defined as recurrence less than 6 months after initial platinum based treatment.

• Participants must be greater than or equal to 18 years of age.

• Participants must have an Eastern Cooperative Group (ECOG) Performance Status (PS) less than or equal to 2.

• Participants must be able to take oral medications.

Exclusion Criteria

• Participants must not have had chemotherapy or radiotherapy within 4 weeks

• Participants must not be receiving any other investigational agents.

• Participants must not have brain metastases

• Participants must not have allergic reactions to minoxidil

• Participants must not have congestive heart failure

• Participants must not have history of cardiac disease

• Participants must not have uncontrolled hypertension

• Participants must not be on dialysis